Adzynma is the first recombinant ADAMTS13 enzyme replacement therapy for treating Congenital Thrombotic Thrombocytopenic Purpura.
Related Keywords
Spero Cataland , Julie Kim , Us Thrombotic Microangiopathy Alliance , Wexner Medical Center , Ohio State University , Drug Administration , Microangiopathy Alliance ,
comparemela.com © 2020. All Rights Reserved.